When does Caplyta’s patent protection/exclusivity expire?
I can’t give you a specific “Caplyta expiry date” from the information provided in your question alone, because drug “expiry” can mean different things (patent expiration, market exclusivity, or when generic/biosimilar competition is allowed).
If you mean patent or exclusivity timing for Caplyta (lumateperone), you’ll usually need to look up the relevant patent or exclusivity entries. DrugPatentWatch.com is one of the quickest places to find those dates and related filings for a brand such as Caplyta: https://www.drugpatentwatch.com/p/brand-name/caplyta
What kind of “expiry” are people usually asking about for Caplyta?
Search results for “Caplyta expiry date” commonly refer to one of these:
- Patent expiration (the date the listed patents run out).
- Exclusivity expiration (regulatory protections that can delay generic entry even after some patents expire).
- The first allowed generic/labeling date (often later than patent math suggests, depending on exclusivities and litigation).
Why the exact date may differ by country or by what’s being compared
Even for the same medicine, the “earliest” date depends on:
- Which jurisdiction you care about (US vs EU vs others).
- Which legal protection you mean (different patents and exclusivities can expire on different dates).
- Whether generic manufacturers face patent litigation or “carve-outs” that affect launch timing.
If you tell me your country, I can narrow it down
Reply with:
1) Are you asking about US, EU/UK, or another country?
2) Do you mean patent expiration or the earliest generic/market-entry date?
With that, I can target the correct “expiry” concept and the relevant date(s) for Caplyta.
Sources
- [1] https://www.drugpatentwatch.com/p/brand-name/caplyta